1
|
Chung M, Ruiz-Cordero R, Lee AY, Joe BN, Kelil T. MRI Evaluation of the Lactating Breast. CURRENT RADIOLOGY REPORTS 2022. [DOI: 10.1007/s40134-022-00395-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Abstract
Purpose of Review
To review the MRI appearance of physiologic lactational changes, common benign pathologies, and malignancies in the lactating breast.
Recent Findings
The prevalence of pregnancy-associated breast cancer has increased as more women delay childbirth and lactation. There is a transient increase in breast cancer risk after delivery when women may be lactating. MRI is more sensitive than mammography and ultrasound for the evaluation of the extent of disease in lactating women.
Summary
Understanding the key MRI findings of benign and malignant pathologies in the lactating breast is critical for accurate diagnosis and prompt evaluation of pregnancy-associated breast cancer.
Collapse
|
2
|
Alran L, Chamming's F, Auriol-Leizagoyen S, Velasco V, Deleau F, Brouste V, Bonhomme B, Ben Rejeb H, Marty M, MacGrogan G. Breast hamartoma: reassessment of an underrecognized breast lesion. Histopathology 2021; 80:304-313. [PMID: 34403159 DOI: 10.1111/his.14544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Revised: 07/29/2021] [Accepted: 08/15/2021] [Indexed: 11/29/2022]
Abstract
AIMS Breast hamartomas are an under-recognized lesion because they lack a distinctive microscopic appearance. Microscopic diagnosis can often conclude "no significant lesion" or "normal breast tissue", leading to repeated biopsies and diagnostic delay. We describe the histological, immunohistochemical and radiological features of breast hamartomas in the aim of identifying specific signs to facilitate their diagnosis and to differentiate them from normal breast and fibroepithelial lesions. METHODS AND RESULTS: Forty-seven breast hamartomas were reassessed (histological diagnosis and imaging features). An immunohistochemical study (ER, PR, CD34, HMGA2) was performed. On breast imaging, hamartomas most often presented as probably benign solid masses with circumscribed margins and variable densities. Histologically, breast hamartomas resembled normal breast, although their stromal component was predominant, separating randomly scattered epithelial elements, with areas of pure collagenous stroma. Pseudo angiomatous stromal hyperplasia (PASH) was present in 93.6% of cases and CD34 antibody highlighted intralobular, perilobular and interlobular distribution of CD34-positive fibroblasts. By comparison, CD34 was mostly expressed in the intralobular normal breast tissue stroma. Hamartoma stromal cells expressed HMGA2, ER and PR in 79%, 66% and 76.3% of our cases, respectively, compared to 7.7%, 23% and 19% in normal breast tissue, respectively (P<0.0001; P=0.0005; P<0.0001). CONCLUSIONS After ascertaining that core needle biopsy is effectively intralesional, breast hamartomas can be diagnosed with confidence by taking into account the presence of stromal changes, PASH, interlobular distribution of CD34-positive fibroblasts, HMGA2 and hormonal receptor stromal expression.
Collapse
Affiliation(s)
- Léonie Alran
- Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, F-33000, Bordeaux, France.,Univ. Bordeaux, F-33000, Bordeaux, France
| | - Foucauld Chamming's
- Department of Radiology, Institut Bergonié, Comprehensive Cancer Centre, F-33000, Bordeaux, France
| | - Sophie Auriol-Leizagoyen
- Department of Surgical Oncology, Institut Bergonié, Comprehensive Cancer Centre, F-33000, Bordeaux, France
| | - Valérie Velasco
- Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, F-33000, Bordeaux, France
| | - Florian Deleau
- Univ. Bordeaux, F-33000, Bordeaux, France.,Department of Radiology, Institut Bergonié, Comprehensive Cancer Centre, F-33000, Bordeaux, France
| | - Véronique Brouste
- Department of Clinical Research and Medical Information, Institut Bergonié, Comprehensive Cancer Centre, F-33000, Bordeaux, France
| | - Benjamin Bonhomme
- Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, F-33000, Bordeaux, France
| | - Houda Ben Rejeb
- Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, F-33000, Bordeaux, France
| | - Marion Marty
- Department of Pathology, Hôpital de Haut Lévêque, Bordeaux University Hospital, F-33000, Bordeaux, France
| | - Gaëtan MacGrogan
- Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, F-33000, Bordeaux, France
| |
Collapse
|